These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 17509878)

  • 1. New syntheses of tetrazolylmethylphenylalanine and O-malonyltyrosine as pTyr mimetics for the design of STAT3 dimerization inhibitors.
    Dourlat J; Valentin B; Liu WQ; Garbay C
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3943-6. PubMed ID: 17509878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands.
    Yao ZJ; King CR; Cao T; Kelley J; Milne GW; Voigt JH; Burke TR
    J Med Chem; 1999 Jan; 42(1):25-35. PubMed ID: 9888830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic.
    Gao Y; Luo J; Yao ZJ; Guo R; Zou H; Kelley J; Voigt JH; Yang D; Burke TR
    J Med Chem; 2000 Mar; 43(5):911-20. PubMed ID: 10715157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of the catechol structural moiety as a Stat3 SH2 domain inhibitor by virtual screening.
    Hao W; Hu Y; Niu C; Huang X; Chang CP; Gibbons J; Xu J
    Bioorg Med Chem Lett; 2008 Sep; 18(18):4988-92. PubMed ID: 18768317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel non-phosphorylated potential antitumoral peptide inhibits STAT3 biological activity.
    Dourlat J; Liu WQ; Sancier F; Edmonds T; Pamonsinlapatham P; Cruzalegui F; Garbay C
    Biochimie; 2009 Aug; 91(8):996-1002. PubMed ID: 19470402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of molecular recognition of STAT3 SH2 domain inhibitors through molecular simulation.
    Park IH; Li C
    J Mol Recognit; 2011; 24(2):254-65. PubMed ID: 21360612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-O-(2-malonyl)tyrosine: a new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides.
    Ye B; Akamatsu M; Shoelson SE; Wolf G; Giorgetti-Peraldi S; Yan X; Roller PP; Burke TR
    J Med Chem; 1995 Oct; 38(21):4270-5. PubMed ID: 7473554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor.
    Coleman DR; Ren Z; Mandal PK; Cameron AG; Dyer GA; Muranjan S; Campbell M; Chen X; McMurray JS
    J Med Chem; 2005 Oct; 48(21):6661-70. PubMed ID: 16220982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis for the binding of high affinity phosphopeptides to Stat3.
    McMurray JS
    Biopolymers; 2008; 90(1):69-79. PubMed ID: 18058821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4'-O-[2-(2-fluoromalonyl)]-L-tyrosine: a phosphotyrosyl mimic for the preparation of signal transduction inhibitory peptides.
    Burke TR; Ye B; Akamatsu M; Ford H; Yan X; Kole HK; Wolf G; Shoelson SE; Roller PP
    J Med Chem; 1996 Mar; 39(5):1021-7. PubMed ID: 8676336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel high-throughput screening system for identifying STAT3-SH2 antagonists.
    Uehara Y; Mochizuki M; Matsuno K; Haino T; Asai A
    Biochem Biophys Res Commun; 2009 Mar; 380(3):627-31. PubMed ID: 19285012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of 3'-carboxy-containing tyrosine derivatives as a new class of phosphotyrosyl mimetics in the preparation of novel non-phosphorylated cyclic peptide inhibitors of the Grb2-SH2 domain.
    Song YL; Tan J; Luo XM; Long YQ
    Org Biomol Chem; 2006 Feb; 4(4):659-66. PubMed ID: 16467940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design, synthesis, and X-ray crystallography of a high-affinity antagonist of the Grb2-SH2 domain containing an asparagine mimetic.
    Furet P; García-Echeverría C; Gay B; Schoepfer J; Zeller M; Rahuel J
    J Med Chem; 1999 Jul; 42(13):2358-63. PubMed ID: 10395476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concise and enantioselective synthesis of Fmoc-Pmp(But)2-OH and design of potent Pmp-containing Grb2-SH2 domain antagonists.
    Li P; Zhang M; Peach ML; Liu H; Yang D; Roller PP
    Org Lett; 2003 Aug; 5(17):3095-8. PubMed ID: 12916990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and evaluation of peptidomimetics containing Freidinger lactams as STAT3 inhibitors.
    Gomez C; Bai L; Zhang J; Nikolovska-Coleska Z; Chen J; Yi H; Wang S
    Bioorg Med Chem Lett; 2009 Mar; 19(6):1733-6. PubMed ID: 19243938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: structural recognition of STAT SH2 domains.
    Gunning PT; Katt WP; Glenn M; Siddiquee K; Kim JS; Jove R; Sebti SM; Turkson J; Hamilton AD
    Bioorg Med Chem Lett; 2007 Apr; 17(7):1875-8. PubMed ID: 17336521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of conformationally constrained Grb2 SH2 domain binding peptides employing alpha-methylphenylalanyl based phosphotyrosyl mimetics.
    Oishi S; Karki RG; Kang SU; Wang X; Worthy KM; Bindu LK; Nicklaus MC; Fisher RJ; Burke TR
    J Med Chem; 2005 Feb; 48(3):764-72. PubMed ID: 15689160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonhydrolyzable phosphotyrosyl mimetics for the preparation of phosphatase-resistant SH2 domain inhibitors.
    Burke TR; Smyth MS; Otaka A; Nomizu M; Roller PP; Wolf G; Case R; Shoelson SE
    Biochemistry; 1994 May; 33(21):6490-4. PubMed ID: 7515682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent inhibition of insulin receptor dephosphorylation by a hexamer peptide containing the phosphotyrosyl mimetic F2Pmp.
    Burke TR; Kole HK; Roller PP
    Biochem Biophys Res Commun; 1994 Oct; 204(1):129-34. PubMed ID: 7524496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding modes of peptidomimetics designed to inhibit STAT3.
    Dhanik A; McMurray JS; Kavraki LE
    PLoS One; 2012; 7(12):e51603. PubMed ID: 23251591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.